News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Although the pandemic may have been at the forefront of readers' minds, they remained interested in the latest advances and controversies in precision oncology.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
